Nyxoah SA (FRA:5YI)

Market Cap	106.10M -72.6%
Revenue (ttm)	10.02M +121.6%
Net Income	-90.09M
EPS	-2.36
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	487
Open	2.680
Previous Close	2.555
Day's Range	2.350 - 2.680
52-Week Range	2.350 - 7.650
Beta	n/a
RSI	31.57
Earnings Date	Mar 19, 2026

About Nyxoah

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2009
• Employees: 184
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5YI

Financial Performance

In 2025, Nyxoah's revenue was 10.02 million, an increase of 121.63% compared to the previous year's 4.52 million. Losses were -90.09 million, 52.1% more than in 2024.